Jingli Yang, Jing Wang, Saeed Yasmeen
Provincial Key Laboratory for Utilization and Conservation of Food and Medicinal Resources in Northern Guangdong, 288 University Ave. Zhejiang District, Shaoguan, Guangdong Province, China.
Department of Neurology, The First Affiliated Hospital of Harbin Medical University, 157 Baojian Road Harbin, Heilongjiang, China 150081.
Stem Cells Int. 2022 May 25;2022:5930244. doi: 10.1155/2022/5930244. eCollection 2022.
Ischemic brain injury is associated with a high rate of mortality and disability with no effective therapeutic strategy. Recently, a growing number of studies are focusing on mesenchymal stem cell-based therapies for neurodegenerative disorders. However, despite having the promising outcome of preclinical studies, the clinical application of stem cell therapy remained elusive due to little or no progress in clinical trials. The objective of this study was to provide a generalized critique for the role of mesenchymal stem cell therapy in ischemic stroke injury, its underlying mechanisms, and constraints on its preclinical and clinical applications. Thus, we attempted to present an overview of previously published reports to evaluate the progress and provide molecular basis of mesenchymal stem cells (MSCs) therapy and its application in preclinical and clinical settings, which could aid in designing an effective regenerative therapeutic strategy in the future.
缺血性脑损伤与高死亡率和残疾率相关,且尚无有效的治疗策略。最近,越来越多的研究聚焦于基于间充质干细胞的神经退行性疾病治疗方法。然而,尽管临床前研究结果很有前景,但由于临床试验进展甚微或毫无进展,干细胞治疗的临床应用仍然难以实现。本研究的目的是对间充质干细胞治疗在缺血性中风损伤中的作用、其潜在机制以及临床前和临床应用的限制进行全面的批判。因此,我们试图概述先前发表的报告,以评估进展情况,并提供间充质干细胞(MSC)治疗的分子基础及其在临床前和临床环境中的应用,这有助于未来设计有效的再生治疗策略。